CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme,
a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that due
to the continued progress in its manufacturing operations this year, its
supply of Thyrogen® (thyrotropin alfa for injection) has been
fully restored. As a result, beginning in November, Genzyme is able to
supply all patient demand globally.
“Genzyme continues to
invest in our manufacturing capabilities and we are dedicated to
delivering high quality product and continuous supply of Thyrogen for
the long term.”
“We are grateful to the Thyroid cancer treatment community for its
ongoing patience and partnership,” said Genzyme’s Vice President and
General Manager of Endocrinology, Alicia Secor. “Genzyme continues to
invest in our manufacturing capabilities and we are dedicated to
delivering high quality product and continuous supply of Thyrogen for
the long term.”
Health care providers should acquire Thyrogen through normal
distribution channels to schedule any new Thyrogen treatments.
About Thyrogen
Thyrogen (thyrotropin alfa for injection) is for patients with
well-differentiated thyroid cancer. Thyrogen is approved as an
adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or
without radioiodine imaging. Thyrogen is also approved in the U.S. and
Europe as an adjunctive treatment for radioiodine ablation of thyroid
tissue remnants in patients who have undergone a near total or total
thyroidectomy for well-differentiated thyroid cancer and who do not have
evidence of metastatic thyroid cancer.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative
therapies for patients affected by rare and debilitating diseases for
over 30 years. We accomplish our goals through world-class research and
with the compassion and commitment of our employees. With a focus on
rare diseases and multiple sclerosis, we are dedicated to making a
positive impact on the lives of the patients and families we serve. That
goal guides and inspires us every day. Genzyme’s portfolio of
transformative therapies, which are marketed in countries around the
world, represents groundbreaking and life-saving advances in medicine.
As a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® and Thyrogen® are registered trademarks
of Genzyme Corporation. All rights reserved.
Forward Looking Statements
This press release contains forward-looking statements as defined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and
expectations with respect to future financial results, events,
operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally
identified by the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product
candidates as well as their decisions regarding labeling and other
matters that could affect the availability or commercial potential of
such products candidates, the absence of guarantee that the products
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group’s
ability to benefit from external growth opportunities as well as those
discussed or identified in the public filings with the SEC and the AMF
made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s
annual report on Form 20-F for the year ended December 31, 2010. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.